
Priority for Finished Medicinal Products: How the Bundestag Is Sacrificing Cannabis Patients — and Why It Will Hardly Save Any Money
In the GKV Cost-Cutting Act, the Bundestag has adopted a priority rule for finished cannabis pharmaceuticals. Flower and pharmacy-compounded formulations are being relegated to the end of the prescribing chain. The German Hemp Association calls it "scandalous," while the Pharmazeutische Zeitung refers to it as a "foreign body in the cost-cutting act." A critical breakdown from the patient's perspective, backed by numbers.
Discover More













